A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2002
12/05/2002	WO2002096921A1 Novel glucose derivative inducing apoptosis, process for producing the same, and use thereof as medicine
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096896A1 Biologically active methylene blue derivatives
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096367A2 Targeted multivalent macromolecules
12/05/2002	WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096357A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
12/05/2002	WO2002062968A3 Micro-tubular materials and cell constructs
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	WO2002009637A3 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	WO2001091734A3 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
12/05/2002	WO2001045577A9 Intervertebral disc treatment devices and methods
12/05/2002	WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002	US20020183855 Tissue repair matrix
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183391 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183381 Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
12/05/2002	US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183362 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
12/05/2002	US20020183360 Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels
12/05/2002	US20020183346 Tricyclic androgen receptor modulator compounds and methods
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
12/05/2002	US20020183318 Novel derivatives of flavones, xanthones and coumarins
12/05/2002	US20020183314 For therapy of acne, male- pattern baldness, sexual dysfunction, impotence, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers
12/05/2002	US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002	US20020183288 Administering to a subject suffering from hyperparathyroidism an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020183264 Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020183261 Oral administration of these can stimulate proliferation of osteoblast, inhibit bone resorption and strengthen bone; can be useful for improvement of osteoporosis, bone fracture, bone pain, etc
12/05/2002	US20020183242 Peptide antiangiogenic drugs
12/05/2002	US20020182698 Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
12/05/2002	US20020182664 Recovering cell components from sample; obtain cells sample, lyse, centrifuge, withdraw fluid, detect cell components
12/05/2002	US20020182650 Inhibitors of binding between proteins and macromolecular ligands
12/05/2002	US20020182646 Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
12/05/2002	US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182265 Lubricious coatings for substrates
12/05/2002	US20020182242 Especially for enhancing the repair of damaged or diseased bone and cartilage tissues.
12/05/2002	US20020182213 Method for the treatment of fibrosis
12/05/2002	US20020182205 Administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.
12/05/2002	DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases
12/05/2002	CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2448956A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448562A1 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448294A1 Method for treating fibrotic diseases or other indications vi
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	CA2447916A1 Tumor endothelial marker 7.alpha. molecules and uses thereof
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/04/2002	EP1261744A2 Estrogen receptor beta variants and methods of detection thereof
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261700A2 Cis acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region
12/04/2002	EP1261644A2 Modulation of the activity of the endothelial cell surface receptor ecrtp/dep-1 in the regulation of angiogenesis
12/04/2002	EP1261643A1 Composition for inhibiting macrophage activity

1 ... 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 ... 820